JSPR250117P25000
- 6.58
- 0.000.00%
Jasper Therapeutics Newsroom
BMO Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $63
Jasper Therapeutics Is Maintained at Market Outperform by JMP Securities
Jasper Therapeutics Analyst Ratings
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
3 Best Stocks to Buy Now, 1/3/2025, According to Top Analysts
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
Analysts Are Bullish on These Healthcare Stocks: Jasper Therapeutics (JSPR), Celldex (CLDX)
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $68
Jasper Therapeutics Analyst Ratings
BMO Capital Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $63
BMO Capital Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $63
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $68
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $60 to $70
Promising Outlook for Jasper Therapeutics: Buy Rating Reinforced by Advancements in Briquilimab
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Buy Rating on Jasper Therapeutics Backed by Strategic Clinical Program Expansion and Promising Preliminary Results
H.C. Wainwright Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $65